← All sectors / The AI transformation
025 · Digital health & care delivery
Care outside the hospital
Curve position
Binding constraint
Payer contracts and reimbursement for remote care.
Why this sector sits at Orbit
We place digital health and care delivery at Orbit. The leading companies are established, and Teladoc's model rests on large partnerships with employers and health plans. Zacks data from spring 2026 showed both Hims & Hers and Teladoc below their five-year median price-to-sales multiples, with both shares down over the prior year. That's the opposite of Flight.
Pockets of growth remain. Hims & Hers had nearly 2.6m subscribers in Q1 2026 and is buying Eucalyptus. But one growing consumer platform isn't a sector with money flooding in.
We would look again if AI-driven care delivery produced accelerating revenue and expanding multiples across several listed companies, not just one.
Reviewed on a two month cycle. The position moves only when a dated, verifiable change in the binding constraint justifies it.
Heatmap / How this sector's stocks are moving
| Stock | Price | 1 Day | 1 Week | 1 Month | Year to date |
|---|---|---|---|---|---|
| $HIMS | $26.66 | +3.74% | −9.07% | −9.54% | −17.89% |
| $TDOC | $9.70 | +9.11% | +40.99% | +68.11% | +38.57% |
| $DOCS | $34.67 | +6.35% | +1.23% | +24.76% | −21.70% |
| $HCAT | $1.59 | +10.42% | −11.67% | −10.17% | −33.47% |
| $OSCR | $35.19 | +8.58% | +15.45% | +8.81% | +144.89% |
| Sector average | +7.64% | +7.39% | +16.39% | +22.08% |
Prices as of November 5, 2026. The sector's move is the equal-weighted average of these listed companies, a market proxy for context, not recommendations. See it on the full heatmap →
Sentiment / The mood in this sector's stocks
Since 2020, Digital health & care delivery has been in Optimism and falling 6 separate times. After those, its stocks beat their usual three months 4 times (67%), by a median of +14.3 points.
Confidence: low, too few past episodes to call an edge.
Healthcare's cost problem is largely a delivery problem: too much care happens in the most expensive setting available. Digital health uses AI, remote monitoring, and virtual visits to move care to cheaper settings, the home above all, and the economics of that shift are finally being reimbursed.
Historical context: telehealth existed for years as a marginal service, then became mainstream out of necessity, then partially receded. What persists is the infrastructure and the reimbursement precedent, both of which AI now makes considerably more useful than a video call ever was.
The structural driver is demographic and financial at once. Aging populations increase chronic disease management demand, clinician shortages cap in person capacity, and value based payment models reward keeping patients out of hospitals, aligning provider incentives with remote care for the first time.
The technology layer spans remote monitoring devices and wearables, AI triage and symptom assessment, virtual care platforms, ambient documentation that removes clerical load, and the revenue cycle automation that attacks healthcare's enormous administrative overhead.
Adoption economics are strongest where a payer saves money immediately: chronic care management, post discharge monitoring that prevents readmission penalties, and behavioral health, where capacity constraints are severe and virtual delivery is clinically appropriate.
The beneficiaries include remote monitoring device makers with recurring service revenue, virtual care platforms with payer contracts, healthcare administrative software vendors, and the pharmacy and diagnostics companies extending services into the home.
The value chain runs from devices through platforms and clinical services to payers and employers who fund it. Value accrues to whoever holds the contracted relationship with the payer, because that is where the savings are measured and shared.
The overlooked layer includes small cap medical device firms adding connectivity, revenue cycle and prior authorization automation vendors, home health staffing and logistics providers, and the interoperability specialists that make fragmented records usable.
Competitive dynamics are consolidating: health systems build or buy digital capability, insurers vertically integrate care delivery, and standalone platforms must prove they lower total cost or get absorbed. Distribution through payers beats direct to consumer economics almost every time.
Risks: reimbursement policy can change with a rule making cycle and reprice an entire business model; clinical validation requirements are demanding; patient engagement is historically weak; and the sector has produced spectacular valuation collapses when growth outran unit economics.
What to watch: reimbursement decisions for remote monitoring and virtual care, payer contract wins, readmission and total cost of care outcomes data, and administrative cost trends at adopting systems. The research follows the money to whoever provably lowers cost.
